SutheeRapisuwonMD

Genitourinary Oncology, Melanoma

Assistant Professor

Overview of Dr. Rapisuwon

Dr. Suthee Rapisuwon is an oncologist in Washington, DC and is affiliated with multiple hospitals in the area, including MedStar Georgetown University Hospital and MedStar Washington Hospital Center. He received his medical degree from Mahidol University Faculty of Medicine and has been in practice 14 years. He specializes in genitourinary oncology and melanoma and is experienced in malignant melanoma, mucosal melanoma, clinical genetics, cutaneous malignant melanoma, and uveal neoplasms.

Office
110 Irving St Nw
Suite C2149
Washington, DC 20010
Book by Phone+1(202) 866-4641

Fax+1 202-444-8829
Is this information wrong?

Education & Training

MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2012 - 2015
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine/Medical Genetics and Genomics, 2007 - 2012
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Medical Genetics and Genomics, 2007 - 2012
Mahidol University Faculty of MedicineClass of 2003

Certifications & Licensure

MD State Medical License 2022 - 2025
DC State Medical License 2012 - 2024
OH State Medical License 2007 - 2013
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
American Board of Medical Genetics and Genomics Clinical Genetics and Genomics

Clinical Trials

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab Start of enrollment: 2017 Jul 26
Terminated
Phase 2
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma Start of enrollment: 2018 Jul 26
Active, not recruiting
Phase 2

Publications & Presentations

PubMed

Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.
Miller, E., Eric J Miller, Tracy L Rose, Benjamin L Maughan, Matthew I Milowsky, Mehmet A Bilen, Bradley C Carthon, Xin Gao, Suthee Rapisuwon, Qianqian Zhao, Menggang ...> ;Cancer. 2024 May 1
8 citations
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma.
Rachel S Goodman, Aleigha Lawless, Rachel Woodford, Faisal Fa'ak, Asha Tipirneni, J Randall Patrinely, Hui Ling Yeoh, Suthee Rapisuwon, Andrew Haydon, Iman Osman, Jani...> ;JAMA Network Open. 2023 Aug 1
46 citations
Dissecting the treatment-naive ecosystem of human melanoma brain metastasis.
Jana Biermann, Johannes C Melms, Amit Dipak Amin, Yiping Wang, Lindsay A Caprio, Alcida Karz, Somnath Tagore, Irving Barrera, Miguel A Ibarra-Arellano, Massimo Andreat...> ;Cell. 2022 Jul 7
6 citations
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
Craig L. Slingluff, Karl D. Lewis, Robert H.I. Andtbacka, John R. Hyngstrom, Mohammed M. Milhem, Svetomir N. Markovic, Tawnya L. Bowles, Omid Hamid, Leonel Hernandez-A...> ;Journal for Immunotherapy of Cancer. 2021 Oct 1
8 citations
PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma.
Geoffrey T. Gibney, Jacob Zaemes, Shelly Shand, Neil J. Shah, David M Swoboda, Kellie Gardner, Arash Radfar, Vesna Petronic-Rosic, Michael J. Reilly, Waddah B. Al-Refa...> ;Journal for Immunotherapy of Cancer. 2021 Oct 1
18 citations
Takotsubo Cardiomyopathy Associated With Checkpoint Inhibitor Therapy: Endomyocardial Biopsy Provides Pathological Insights to Dual Diseases.
Michael T Serzan, Suthee Rapisuwon, Jayashree Krishnan, Ian C Chang, Ana Barac> ;JACC. Cardiooncology. 2021 Jun 1
106 citations
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma
J. Randall Patrinely, Rebecca N. Johnson, Aleigha Lawless, Prachi Bhave, Amelia Sawyers, Maya Dimitrova, Hui Ling Yeoh, Marisa Palmeri, Fei Ye, Run Fan, Elizabeth J. D...> ;JAMA Oncology. 2021 May 1
2 citations
A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis.
J. Randall Patrinely, Elisa Funck-Brentano, Khang Nguyen, Suthee Rapisuwon, Joe-Elie Salem, Geoffrey T. Gibney, Matteo S. Carlino, Douglas B. Johnson> ;The Oncologist. 2021 Mar 1
31 citations
Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint i...
Suthee Rapisuwon, Benjamin Izar, Cory Batenchuk, Alexandre Avila, Shaolin Mei, Peter K. Sorger, Jerry M. Parks, Sarah J. Cooper, David Wagner, Jay Zeck, Aline Charabat...> ;Journal for Immunotherapy of Cancer. 2019 Mar 4
36 citations
Clinical characterization of colitis arising from anti-PD-1 based therapy
Daniel Y. Wang, Meghan J. Mooradian, Dae Won Kim, Neil J. Shah, Sarah E. Fenton, Robert M. Conry, Rutika Mehta, Ann W. Silk, Alice Zhou, Margaret L. Compton, Rami N. A...> ;Oncoimmunology. 2019 Jan 2
222 citations
High response rate to PD-1 blockade in desmoplastic melanomas
Zeynep Eroglu, Jesse M. Zaretsky, Siwen Hu-Lieskovan, Dae Won Kim, Alain Algazi, Douglas B. Johnson, Elizabeth Liniker, Ben Kong, Rodrigo Ramella Munhoz, Suthee Rapisu...> ;Nature. 2018 Jan 10
94 citations
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Eileen Shiuan, Kathryn E. Beckermann, Alpaslan Özgün, Ciara Marie Kelly, Meredith Ann McKean, Jennifer L. McQuade, Mary Ann Thompson, Igor Puzanov, John P. Greer, Suth...> ;Journal for Immunotherapy of Cancer. 2017 Feb 21
59 citations
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Bridgette A. Kanz, Megan H. Pollack, Romany A. N. Johnpulle, Igor Puzanov, Leora Horn, Alicia K. Morgans, Jeffrey A. Sosman, Suthee Rapisuwon, R. Martin Conry, Zeynep ...> ;Journal for Immunotherapy of Cancer. 2016 Oct 18
9 citations
Discordance Between Cobas BRAF V600 Testing and VE1 Immunohistochemistry in a Melanoma Patient With Bone Marrow Metastases
Suthee Rapisuwon, Klaus J. Busam, Kellie Parks, Paul B. Chapman, Elsie Lee, Michael B. Atkins> ;The American Journal of Dermatopathology. 2016 Sep 1
87 citations
Circulating biomarkers to monitor cancer progression and treatment
Suthee Rapisuwon, Eveline E. Vietsch, Anton Wellstein> ;Computational and Structural Biotechnology Journal. 2016 Jan 1
5 citations
Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
Suthee Rapisuwon, Kellie A Parks, Waddah B. Al-Refaie, Michael B. Atkins> ;Melanoma Research. 2014 Oct 1
67 citations
Phase II Trial of Imatinib in AIDS-Associated Kaposi's Sarcoma: AIDS Malignancy Consortium Protocol 042
Henry B. Koon, Susan E. Krown, Jeannette Y. Lee, Kord Honda, Suthee Rapisuwon, Zhenghe Wang, David M. Aboulafia, Erin Reid, Michelle A. Rudek, Bruce J. Dezube, Ariela Noy> ;Journal of Clinical Oncology. 2014 Feb 10
7 citations
Multiple muscle cell alterations in a case of encephalomyopathy.
Hisashi Fujioka, Bernard Tandler, Mariana G. Rosca, Shawn E. McCandless, Bashar Katirji, Mark L. Cohen, Suthee Rapisuwon, Charles L. Hoppel> ;Ultrastructural Pathology. 2014 Jan 22
152 citations
Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes.
Christian P. Kratz, Suthee Rapisuwon, Helen D. Reed, Henrik Hasle, Philip S. Rosenberg> ;American Journal of Medical Genetics. Part C, Seminars in Medical Genetics. 2011 May 15
Join now to see all

Lectures

Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma.
2019 ASCO Annual Meeting - 6/1/2019
Identification of a gene expression signature predictive of clinical benefit in patients with advanced mucosal melanoma (MCM) treated with immune checkpoint blockade.
2019 ASCO Annual Meeting - 6/1/2019
Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFmM): I...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018